Merck Serono targets convenient, affordable medicines for patients at risk.
D000319:Adrenergic beta-Antagonists / Q000191:economics / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000191:economics / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000191:economics / Q000209:etiology; D004232:Diuretics / Q000191:economics / Q000627:therapeutic use; D004338:Drug Combinations; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics*; D004359:Drug Therapy, Combination; D006297:Health Services Accessibility / Q000191:economics*; D006801:Humans; D018570:Risk Assessment; D013019:South Africa; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D004232:Diuretics; D004338:Drug Combinations